Myo-inositol, also known as inositol (cyclohexanehexol), is a cyclic carbohydrate with six hydroxyl groups. For a long time, it was considered a B vitamin (vitamin B₆). However, it is not considered an essential nutrient because it is formed from glucose. Each kidney makes around 2 g of myo-inositol per day, and the average dietary intake is 0.5–1.0 g/day. The liver and brain also synthesise myo-inositol, although at much lower amounts compared with the kidneys. Importantly, however, in the brain, myo-inositol levels reach concentrations 10-fold to 15-fold greater than that of blood, and there is limited uptake of myo-inositol from systemic circulation.

Unfortunately, no requirement for dietary inositol in humans has been determined despite demonstration of signs of inositol deficiency in several animal species. Importantly, dietary caffeine intake (particularly coffee) increases the need for myo-inositol. Increasing age, antibiotic use, sugar and refined carbohydrate intake, sodium deficiency, insulin resistance, and type 1 and 2 diabetes all increase the need for myo-inositol.

Myo-inositol is synthesised from glucose, which eventually gets converted to free myo-inositol. Free inositol can also be obtained by recycling inositol-triphosphate (IP₃) and inositol-bisphosphate (IP₂). Thus, taking myo-inositol likely spares IP₃ and IP₂. The biosynthesis of myo-inositol requires nicotinamide adenine dinucleotide+ and magnesium. Thus, a deficiency in either may lead to a deficiency in myo-inositol. Myo-inositol is the structural bases of many hormonal secondary messengers, particularly IP₃ and phosphatidylinositol phosphate lipids (PIP₂/PIP₃) and inositol glycans. Myo-inositol exists in many phosphorylated forms, such as monophosphorylated forms (Ins-1-P, Ins-3-P or Ins-4-P), pyrophosphate forms (PP-InsP₃, PP-InsP₂, PP₂InsP, or (PP)₂-InsP₄) and a hexaphosphorylated form (IP₆ or phytic acid). Furthermore, inositol is essential for normal cell growth and survival, development and function of peripheral nerves, osteogenesis and reproduction.

Myo-inositol is a sugar alcohol or polyol, and it mediates signal transduction in response to
several hormones, neurotransmitters and growth factors and participates in osmoregulation. 20 There are eight other inositol isomers, all of which are formed from the epimerisation of myo-inositol. Myo-inositol also leads to the formation of inositol phosphates, phosphatidylinositol, phosphatidylinositol–phosphates, glycosyl–phosphatidylinositol, inositol–phosphoglycans, and inositol ethers and esters. 1

Myo-inositol can either be present in free form or bound to phospholipids or inositol phosphate derivatives. 2 Additionally, myo-inositol is a structural component of the cell membrane as it is needed in the formation of phosphatidylinositol. 1 Myo-inositol is also important for insulin signalling as it makes up many secondary messengers in response to insulin. Elevated glucose levels decrease the absorption and biosynthesis of myo-inositol and increase its degradation and urinary excretion. 21 Insulin resistance and elevated glucose levels reduce inositol uptake into tissues. Myo-inositol levels are higher in tissues that use large amounts of glucose, such as the brain, heart and ovaries. D-chiro-inositol (DCI) is higher in tissues requiring glucose storage, such as liver and muscles. Insulin resistance impairs the conversion of myo-inositol to DCI in muscles, fat and liver. Increased urinary losses of myo-inositol have been consistently found in those with type 1 and type 2 diabetes. 21

Once myo-inositol enters the cell, it is transformed into phosphatidyl-myoinositol, which then converts to inositol–triphosphate acting as an intracellular second messenger for insulin, follicle-stimulating hormone (FSH) and thyroid-stimulating hormone (TSH). 22 Myo-inositol and DCI are the two main inositol stereoisomers in the human body. DCI is formed from the conversion of myo-inositol via an insulin-dependent mechanism. 23

**INOSITOL TRANSPORT AND EXCRETION**

Myo-inositol is actively transported by intestinal cells in a Na+-dependent manner. 24 Virtually all of the free myo-inositol (99.8%) is absorbed from the human gastrointestinal tract through this active transport system involving the Na+/K+-ATPase. 25 Thus, sodium helps with absorption of myo-inositol in the intestine and its reabsorption in the kidneys. 1 Additionally, sodium moves myo-inositol into tissues cells. The major transport system for myo-inositol uptake into mammalian cells is a saturable carrier-mediated active process driven by energy from the sodium gradient. Indeed, two sodium ions transport one myo-inositol into the brain and peripheral tissues via sodium-dependent myo-inositol transporter 1 (SMIT1) and sodium-dependent myo-inositol transporter 2 (SMIT2). 26 Inositol can be transported from extracellular fluid via three transporters: SMIT1, SMIT2 and H+-myo-inositol transporter, which cotransports myo-inositol with H+. SMIT1 and SMIT2 cotransport two sodium ions to generate enough energy to actively transport myo-inositol into the cell. SMIT1 and SMIT2 help drive myo-inositol into the brain, and the intestinal absorption and reabsorption in the kidney depends on SMIT2, which is inhibited by glucose. 7 SGLT1/2 inhibitors reduce myo-inositol absorption/reabsorption. Galactose and glucose reduce myo-inositol uptake and incorporation into phospholipids. This occurs even under physiological concentrations of glucose. 27 Elevated blood glucose depletes myo-inositol levels in nervous tissue due to a competitive inhibition of the sodium-dependent myo-inositol uptake. 110 Glucose and other sugars reduce the intestinal absorption and kidney reabsorption of myo-inositol. 1 Manganese helps to incorporate free inositol into the phosphoinositides and the formation of phosphatidylinositol. 28

In rats, myo-inositol accumulates rapidly (within 1 hour) after absorption in large amounts in the thyroid, sex glands and reproductive fluids. Other tissues, including the pituitary, prostate, liver and spleen concentrate myo-inositol. Importantly, all organs of the male reproductive tract, except for the testis, have myo-inositol levels that are 10–30 times that of blood. This is likely because the testis can endogenously synthesise inositol, as can the brain, kidney and liver. About half of the free inositol in rabbit brain is from endogenous production, the other half coming from blood. The kidneys are the main organ to catabolise inositol into CO₂. However, the kidneys may metabolise inositol into other metabolites that are more readily able to cross the blood–brain barrier. 7

The organs of the male reproductive tract (and epididymal, vesicular and prostatic fluids) are rich in free myo-inositol. Moreover, high levels of myo-inositol have been measured in mammalian semen, suggesting its importance in male reproductive health. 7 Unbound free myo-inositol levels are high in the brain, cerebrospinal fluid, choroid plexus, small intestine and kidney, whereas myo-inositol is primarily in its phospholipid-bound form in the liver, skeletal muscle and heart. Myo-inositol is also an important constituent of breast milk. The organs that concentrate myo-inositol the most are the kidneys, organs of the reproductive tract and the brain. Except for the brain, myo-inositol tissue content is highly dependent on dietary inositol, suggesting that a lack of inositol in the diet could lead to suboptimal tissue levels. 1 29

**MYO-INOSITOL AND DCI FOR POLYCYSTIC OVARY SYNDROME (PCOS)**

PCOS affects 5%–21% of women during their reproductive life. 20 Insulin resistance is a frequent finding in patients with PCOS, regardless of body mass index (BMI). Indeed, around 70%–80% of women with PCOS and central obesity and 15%–30% of lean women with PCOS have insulin resistance and compensatory hyperinsulinaemia. The hyperinsulinaemia can increase ovarian androgen synthesis via amplified luteinising hormone (LH) secretion, which also affects ovarian stimulation.

Insulin uses inositol phosphoglycans (IPGs) as secondary messengers, which control the oxidative and non-oxidative metabolisms of glucose as well as...
the uptake of glucose by GLUT4. Additionally, other hormones such as TSH and FSH use IPGs as secondary messengers. Both myo-inositol and DCI are involved in the intracellular transmission of insulin’s metabolic signal and are also important for the oxidative use of glucose and its storage as glycogen.

The epimerase that converts myo-inositol to DCI is insulin dependent, and this conversion is reduced in insulin resistance tissues. There is a reduction in urinary DCI and an increase in urinary myo-inositol excretion in humans and animals with type 2 diabetes. Patients without PCOS undergoing a glucose tolerance test have a threefold lower release of DCI than controls. Thus, a deficiency in myo-inositol, or an impairment in the function/expression of the enzyme that converts myoinositol to DCI, can lead to insulin resistance (which can further lead to a deficiency in DCI since the epimerase that converts myo-inositol to DCI is insulin sensitive).

DCI at 1200 mg/day given to obese patients with PCOS for 8 weeks significantly reduced insulin area under the curve after an oral glucose tolerance test by 62% and free testosterone levels by 55%. Diastolic and systolic blood pressure significantly decreased by 4 mm Hg, and triglyceride concentrations decreased from 184 mg/dL to 110 mg/dL compared with placebo. Lastly, ovulation was restored in 86% of patients receiving DCI vs only 27% on the placebo group. Lean patients with PCOS also benefit when myo-inositol is combined with DCI regarding restoring the regularity of their menstrual cycle.

Unfer and colleagues looked at 12 studies and found that myo-inositol (with or without DCI) improves oocyte maturation, pregnancy rates and hormonal parameters such as LH, LH:FSH ratio, testosterone, androstenedione, insulinemia and Homeostatic Model Assessment (HOMA) index in patients with PCOS. The glucose:insulin ratio, total cholesterol and high-density lipoprotein (HDL) concentrations also improved.

In a 12-week randomised controlled study in 50 overweight women with PCOS, 2 g of myo-inositol (with 200 mcg of folic acid) in the morning led to significant reductions in plasma LH, prolactin, testosterone, insulin and LH:FSH ratio and an improvement in insulin sensitivity. Delivery rate also significantly improved with myo-inositol, and menstrual cyclicity was restored in all amenorrheic and oligomenorrheic subjects. No changes in menstrual cyclicity occurred in the patients treated with folic acid alone. Additionally, Kamenov et al. found that 2 g/day of myo-inositol improved ovulation leading to higher rates of pregnancy and delivery. A reduction in BMI and an improvement in insulin resistance were also noted. This study also found that around 61.7% of patients with PCOS ovulated after taking myo-inositol, and in those who were resistant, once clomiphene was added, 72.2% ovulated. Several meta-analyses of randomised controlled trials have shown that myo-inositol mono-therapy, and when combined with DCI, is effective in patients with PCOS. However, myo-inositol is better tolerated than metformin, making it more acceptable for PCOS women. Another meta-analysis concluded that myo-inositol is beneficial in PCOS and non-PCOS women undergoing in vitro fertilisation.

**INOSITOLS IN INSULIN SIGNALLING AND GLUCOSE METABOLISM**

Much of the benefits of high-fibre diets in regard to cancer reduction and improvements in glucose metabolism are thought to be due to the IP6 content. Insulin-resistant states lead to increased urinary losses of myoinositol primarily due to the glucose-mediated inhibition of myoinositol reabsorption by the kidneys. A reduction in myoinositol decreases DCI, in which a deficiency in both contributes to insulin resistance in skeletal muscle, liver and fat cells. Myo-inositol is involved in fertility, oogenesis, embryogenesis, regenerative processes (transcription control, mRNA export and DNA repair) and fat metabolism.

Myo-inositol inhibits duodenal glucose absorption and reduces blood glucose levels via a competitive affinity for the same transporter system. Ironically, however, myo-inositol improves muscle glucose uptake. Glucose also impairs cellular uptake of myo-inositol. Sodium–glucose transport inhibitors prevent glucose and inositol uptake. Inositol is transported into the cell by sodium ion-coupled transporters, and glucose can competitively inhibit the uptake of inositol via this pathway. This is likely why diabetic nerves are depleted in inositol. Glucose can also deplete myoinositol via activation of the glucose–sorbitol pathway, whereby glucose is converted to sorbitol by aldose reductase and then to fructose, which is increased in states of elevated glucose. The rise in sorbitol elevates intracellular osmolality, which inhibits the uptake of other osmolytes, including myo-inositol, by downregulating the expression of their carriers. In fact, aldose reductase inhibition restores myoinositol levels by reducing sorbitol levels. Thus, states of elevated glucose increase inositol needs.

Abnormalities in plasma and urine myo-inositol/DCI may be an early marker of insulin resistance and type 2 diabetes. Furthermore, a lack of myo-inositol worsens insulin resistance, impairs antioxidant defenses and increases oxidative glycation stress. Phospholipase C releases IPGs, containing either myo-inositol or DCI, both of which have insulin-mimetic activity and act as second messengers downstream of insulin receptors. Inositol compounds also reduce hyperglycaemia in a dose-dependent fashion and promote glycogen stores in muscle.

The conversion of myo-inositol to DCI is severely impaired with insulin resistance in insulin-sensitive tissues (muscle, fat and liver). Thus, a low DCI:myo-inositol ratio may represent a measure of insulin resistance. Indeed, low DCI levels are typical in the urine and muscle tissue of patients with type 2 diabetes. A lack of DCI in the urine is related with insulin resistance in both patients with type 2 and healthy controls.
will reduce DCI levels and worsen insulin resistance. Plasma and tissue levels of DCI and IPGs are reduced in patients with PCOS with insulin resistance and in patients with type 2 diabetes.33

A paradox exists in patients with PCOS, whereby the ovaries do not become insulin resistant, even though these patients have insulin resistance and issues with ovulation. In fact, there is a greater conversion of myo-inositol to DCI in the ovaries, which leads to low myo-inositol in the ovary and high DCI, leading to biological dysfunctions.51 This is why combining both myo-inositol (to fix the low myo-inositol in the ovary) and DCI (to fix the low levels of DCI in the liver, skeletal muscle and fat) has synergistic benefits. Indeed, impairment in ovary function in patients with PCOS is associated with an increase in the DCI:myo-inositol ratio.32

In sites of diabetic microvascular complications (kidney, sciatic, nerve, retina and lens), a concomitant depletion of intracellular myo-inositol and accumulation of intracellular sorbitol is commonly observed. In diabetes, there is reduced cellular myo-inositol uptake, altered myo-inositol biosynthesis, enhanced efflux due to sorbitol intracellular accumulation and increased degradation leading to myo-inositol depletion. The competition between myo-inositol and glucose for myo-inositol transporters occurs due to the similarity in their structure.47

In the testes of diabetic animals, there is a significant 50% reduction in the activity of 1-D-myo-inositol-phosphate synthase, the enzyme that regulates the first step in myo-inositol biosynthesis.7 However, other tissues (kidney, brain and nerves) do not show a reduction in enzyme activity. There is an increase in the enzyme that breaks down myo-inositol in the kidney of diabetic, insulin resistant, and hypertensive rats and mice.7

**How states of insulin resistance deplete myo-inositol**

- Reduced synthesis (reduced biosynthesis via decreased enzyme function).
- Increased breakdown (upregulation in the enzyme that breaks down myo-inositol).
- Decreased penetration into cells (competition with glucose).
- Greater cellular release/reduced cellular uptake (sorbitol competition).
- Greater loss in the urine (glucose competes for myo-inositol reabsorption in the kidneys).

Myo-inositol at 2 g twice per day reduces the incidence of gestational diabetes by 65.0%–87.3%.53,54 These studies also noted reduced requirements for insulin, delivery at a later gestational age and fewer episodes of neonatal hypoglycaemia. In a randomised, placebo-controlled study, 80 women were placed on either myo-inositol 2 g two times per day or placebo. The group treated with myo-inositol had significant improvements in diastolic blood pressure (−11%), HOMA index value (−75%), serum triglycerides (−20%) and HDL (+22%).55 In 69 women with gestational diabetes, 2 g of myo-inositol two times per day significantly improved fasting glucose and insulin and Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) value compared with control.56 Furthermore, adiponectin increased in the myo-inositol group, but decreased in the control group.76 In 80 postmenopausal women with metabolic syndrome, 2 g/day of myo-inositol improved blood glucose, insulin, HOMA-IR value, triglycerides, total and HDL cholesterol and blood pressure compared with placebo.57 Additionally, there was a significant improvement in BMI and waist circumference in the myo-inositol group versus baseline after 12 months. After taking myo-inositol, eight women (20%) no longer had metabolic syndrome compared with only one in the control group.

Myo-inositol is involved in many cell functions, especially as a precursor of phosphatidylinositol and phosphoinositides. Since the Km for the biosynthesis of phosphatidylinositol from myo-inositol is relatively high…a depletion of intracellular myo-inositol could have a negative impact on the synthesis and availability of phosphatidylinositol and phosphatidylinositol phosphates in cells.7

Altered phosphatidylinositol turnover has been associated with myo-inositol deficiency in the sciatric nerve of diabetic rats.58 Altered Na+/K-ATPase activity may be a direct consequence of intracellular myo-inositol deficiency and a potential reason for diabetic microvascular complications. Indeed, altered Na+/K-ATPase activity impairs nerve conductivity and may cause diabetic neuropathy (axonal degeneration and demyelination) through inhibition of cell growth, transformation and differentiation. A depletion of myo-inositol, caused by elevated glucose levels, may be directly responsible for diabetic glomerulosclerosis and proteinuria as well as tubulointerstitial fibrosis, which would reduce the reabsorption of inositol and other nutrients (electrolytes and amino acids) back into the body.7

…the myo-inositol depletion observed under hyperglycemic conditions in insulin insensitive tissues seems to contribute to the development of diabetic microvascular complications, together with the four major and more recognized pathways, namely: increased Advanced Glycation End products (AGEs) formation, activation of protein kinase C (PKC), increased hexosamine and sorbitol pathways.7

Consequences of myo-inositol deficiency7

- Altered Na+-K-ATPase activity.
- Diabetic neuropathy, nephropathy and retinopathy.
- Diabetic nephropathy.
- Worsening of insulin resistance.
- Elevated fasting and postprandial glucose and insulin levels.

Individuals with type 2 diabetes have a decreased urinary excretion of chiro-inositol and a 10-fold higher urinary excretion of myo-inositol compared with healthy people.31 Elevated urinary myo-inositol levels in
individuals with type 2 diabetes have been known since 1859. In monkeys, there is a progressive increase in myo-inositol levels in the urine when going from normal to obese non-diabetic to diabetic, which correlates with the severity of insulin resistance. An increased myo-inositol:DCI ratio in the urine has been proposed as an index of insulin resistance in humans. A decrease of DCI in insulin target tissues could reduce insulin signal transduction and further contribute to insulin resistance in those tissues. There are also depleted plasma levels of the DCI in patients with PCOS. In autopsy and biopsy studies of the muscles of individuals with type 2 diabetes, there is an increased myo-inositol:DCI ratio. Furthermore, chiro-inositol is decreased in the muscle, urine and hemodialysate of individuals with type 2 diabetes versus controls. There is a fourfold to fivefold decrease in the conversion of myo-inositol to DCI in type 2 diabetic rats due to a twofold to threefold decrease in epimerase activity. The reduction in epimerase activity is likely caused by myo-inositol deficiency, insulin insensitivity or a combination of both.

Insulin resistance and diabetes lead to:
- Abnormally low levels of DCI in urine, plasma and insulin-sensitive tissues (liver, muscle and fat).
- Excessive urinary excretion of myo-inositol.
- Intracellular myo-inositol deficiency in insulin-sensitive tissues (kidney, ovary, sciatic nerve, lens and retina).

**DIABETES, GESTATIONAL DIABETES AND METABOLIC SYNDROME**

In gestational diabetes, myo-inositol at 2 g two times per day for 8 weeks improves fasting insulin and glucose levels. In pregnant women with a family history of type 2 diabetes, myo-inositol at 2 g two times per day throughout pregnancy significantly reduces fasting and 1-hour glucose levels after an oral glucose tolerance test and reduces the incidence of gestational diabetes by 40% (6.0% vs 15.3% in the placebo group). Improvements were also noted in fetal macrosomia and high mean fetal weight. Blood pressure, total and low-density lipoprotein cholesterol, and serum triglycerides were also reduced and HDL was increased.

Myo-inositol lowers serum insulin and improves insulin resistance approximately twofold better compared with pioglitazone or metformin, which are considered the gold standard medications in those with impaired glucose tolerance. Animal studies confirm that high doses of myo-inositol, given acutely or chronically, reduce blood glucose levels to an oral glucose load via improvements in peripheral insulin sensitivity by an enhanced GLUT-4 translocation to the plasma membrane in response to hyperglycaemia in skeletal muscle.

**DIABETIC COMPLICATIONS**

Diabetic tissues, such as the kidney, sciatic nerve, lens and retina, are depleted in myo-inositol. Thus, myo-inositol supplementation may help to prevent or delay the development of diabetic neuropathy, nephropathy and/or retinopathy.

**NEUROPATHY, NEPHROPATHY AND CATARACTS**

Myo-inositol supplementation in diabetic rats restores depleted myo-inositol intracellular levels and reduces or prevents impaired motor nerve conduction velocity despite persistent hyperglycaemia and elevated nerve intracellular levels of sorbitol and fructose. Myo-inositol may also benefit motor nerve conduction velocity in diabetics. Myo-inositol also prevents defects in axonal transport and motor nerve conduction velocity in diabetic rats. In patients with symptomatic distal symmetrical diabetic polyneuropathy, a high myo-inositol diet significantly increases median sensory and the sural sensory nerve conduction velocities. Myo-inositol supplementation reverses elevated glucose-induced reductions in cell proliferation and increased procollagen transcription and secretion in proximal tubule cells of the kidney. Myo-inositol supplementation can restore depleted intracellular myo-inositol levels in the lens of diabetic rats and reduce cataract formation.

Factors that deplete inositol include: 7 9 64 65
- Insulin resistance
- Elevated glucose levels
- Low sodium intake
- Caffeine (coffee, tea, etc)
- Kidney damage
- Intestinal damage
- Lithium
- Valproic acid
- Magnesium deficiency

**CONCLUSION**

Myo-inositol should be considered in patients with insulin resistance, metabolic syndrome, type 1 diabetes, type 2 diabetes, PCOS and those with or at risk of gestational diabetes. Elevated levels of glucose reduce myo-inositol levels in tissues and increase its breakdown and elimination via the kidneys. Myo-inositol has been used safely for decades in many studies in those with insulin resistance and PCOS.

**Contributors** All authors contributed to the final manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** JJD is director of scientific affairs at AIDP. JJD is affiliated with companies that sell myo-inositol. JHO owns a supplement company.

**Patient consent for publication** Not applicable.

**Ethics approval** This study does not involve human participants.
REFERENCES


